BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

462 related articles for article (PubMed ID: 32515499)

  • 1. Higher levels of IL-6 early after tocilizumab distinguish survivors from nonsurvivors in COVID-19 pneumonia: A possible indication for deeper targeting of IL-6.
    Quartuccio L; Sonaglia A; Pecori D; Peghin M; Fabris M; Tascini C; De Vita S
    J Med Virol; 2020 Nov; 92(11):2852-2856. PubMed ID: 32515499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical outcomes in COVID-19 patients treated with tocilizumab: An individual patient data systematic review.
    Antwi-Amoabeng D; Kanji Z; Ford B; Beutler BD; Riddle MS; Siddiqui F
    J Med Virol; 2020 Nov; 92(11):2516-2522. PubMed ID: 32436994
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical characteristics and predictors of survival in adults with coronavirus disease 2019 receiving tocilizumab.
    Morrison AR; Johnson JM; Griebe KM; Jones MC; Stine JJ; Hencken LN; To L; Bianchini ML; Vahia AT; Swiderek J; Ramesh MS; Peters MA; Smith ZR
    J Autoimmun; 2020 Nov; 114():102512. PubMed ID: 32646770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tocilizumab for the Treatment of COVID-19-Induced Cytokine Storm and Acute Respiratory Distress Syndrome: A Case Series From a Rural Level 1 Trauma Center in Western Pennsylvania.
    Suresh K; Figart M; Formeck S; Mehmood T; Abdel Salam M; Bassilly D
    J Investig Med High Impact Case Rep; 2021; 9():23247096211019557. PubMed ID: 34105382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tocilizumab in SARS-CoV-2 Patients with the Syndrome of Cytokine Storm: A Narrative Review.
    Kulanthaivel S; Kaliberdenko VB; Balasundaram K; Shterenshis MV; Scarpellini E; Abenavoli L
    Rev Recent Clin Trials; 2021; 16(2):138-145. PubMed ID: 32940187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tocilizumab challenge: A series of cytokine storm therapy experiences in hospitalized COVID-19 pneumonia patients.
    Borku Uysal B; Ikitimur H; Yavuzer S; Ikitimur B; Uysal H; Islamoglu MS; Ozcan E; Aktepe E; Yavuzer H; Cengiz M
    J Med Virol; 2020 Nov; 92(11):2648-2656. PubMed ID: 32484930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytokine Profiles Before and After Immune Modulation in Hospitalized Patients with COVID-19.
    Azmy V; Kaman K; Tang D; Zhao H; Dela Cruz C; Topal JE; Malinis M; Price CC
    J Clin Immunol; 2021 May; 41(4):738-747. PubMed ID: 33459964
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tocilizumab improves survival in severe COVID-19 pneumonia with persistent hypoxia: a retrospective cohort study with follow-up from Mumbai, India.
    Gokhale Y; Mehta R; Kulkarni U; Karnik N; Gokhale S; Sundar U; Chavan S; Kor A; Thakur S; Trivedi T; Kumar N; Baveja S; Wadal A; Kolte S; Deolankar A; Pednekar S; Kalekar L; Padiyar R; Londhe C; Darole P; Pol S; Gokhe SB; Padwal N; Pandey D; Yadav D; Joshi A; Badgujar H; Trivedi M; Shah P; Bhavsar P
    BMC Infect Dis; 2021 Mar; 21(1):241. PubMed ID: 33673818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Experience of using tocilizumab for treatment in Indonesian patients with severe COVID-19.
    Widysanto A; Kurniawan A; Lugito NPH; Yuniarti M; Gunawan C; Angela ; Wiryanto J; Levinna ; Pradhana TM
    Cytokine; 2021 Feb; 138():155393. PubMed ID: 33333393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IL-6 serum levels predict severity and response to tocilizumab in COVID-19: An observational study.
    Galván-Román JM; Rodríguez-García SC; Roy-Vallejo E; Marcos-Jiménez A; Sánchez-Alonso S; Fernández-Díaz C; Alcaraz-Serna A; Mateu-Albero T; Rodríguez-Cortes P; Sánchez-Cerrillo I; Esparcia L; Martínez-Fleta P; López-Sanz C; Gabrie L; Del Campo Guerola L; Suárez-Fernández C; Ancochea J; Canabal A; Albert P; Rodríguez-Serrano DA; Aguilar JM; Del Arco C; de Los Santos I; García-Fraile L; de la Cámara R; Serra JM; Ramírez E; Alonso T; Landete P; Soriano JB; Martín-Gayo E; Fraile Torres A; Zurita Cruz ND; García-Vicuña R; Cardeñoso L; Sánchez-Madrid F; Alfranca A; Muñoz-Calleja C; González-Álvaro I;
    J Allergy Clin Immunol; 2021 Jan; 147(1):72-80.e8. PubMed ID: 33010257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tocilizumab as a Treatment for 'Cytokine Storm Syndrome' in COVID-19: A Case Report.
    Syam AF; Pitoyo CW; Suhendro S; Zulkarnain B; Indrasari ND; Aditianingsih D; Irawan C; Susilo A; Rumende CM; Wijaya IP; Ibrahim F; Rasmin M; Alwi I; Makmun D
    Acta Med Indones; 2021 Apr; 53(2):194-201. PubMed ID: 34251348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tocilizumab in patients with severe COVID-19: A single-center observational analysis.
    Knorr JP; Colomy V; Mauriello CM; Ha S
    J Med Virol; 2020 Nov; 92(11):2813-2820. PubMed ID: 32628003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tocilizumab therapy for severely-ill COVID-19 pneumonia patients: a single-centre retrospective study.
    Iqtadar S; Khan A; Mumtaz SU; Pascual-Figal DA; Livingstone S; Abaidullah S
    J Physiol Pharmacol; 2022 Aug; 73(4):. PubMed ID: 36696245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tocilizumab for Severe Worsening COVID-19 Pneumonia: a Propensity Score Analysis.
    Roumier M; Paule R; Vallée A; Rohmer J; Ballester M; Brun AL; Cerf C; Chabi ML; Chinet T; Colombier MA; Farfour E; Fourn E; Géri G; Khau D; Marroun I; Ponsoye M; Roux A; Salvator H; Schoindre Y; Si Larbi AG; Tchérakian C; Vasse M; Verrat A; Zuber B; Couderc LJ; Kahn JE; Groh M; Ackermann F;
    J Clin Immunol; 2021 Feb; 41(2):303-314. PubMed ID: 33188624
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial.
    Declercq J; Van Damme KFA; De Leeuw E; Maes B; Bosteels C; Tavernier SJ; De Buyser S; Colman R; Hites M; Verschelden G; Fivez T; Moerman F; Demedts IK; Dauby N; De Schryver N; Govaerts E; Vandecasteele SJ; Van Laethem J; Anguille S; van der Hilst J; Misset B; Slabbynck H; Wittebole X; Liénart F; Legrand C; Buyse M; Stevens D; Bauters F; Seys LJM; Aegerter H; Smole U; Bosteels V; Hoste L; Naesens L; Haerynck F; Vandekerckhove L; Depuydt P; van Braeckel E; Rottey S; Peene I; Van Der Straeten C; Hulstaert F; Lambrecht BN
    Lancet Respir Med; 2021 Dec; 9(12):1427-1438. PubMed ID: 34756178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Repurposed Tocilizumab in Patients with Severe COVID-19.
    Tian J; Zhang M; Jin M; Zhang F; Chu Q; Wang X; Chen C; Yue H; Zhang L; Du R; Zhao D; Zeng Z; Zhao Y; Liu K; Wang M; Hu K; Miao X; Zhang H
    J Immunol; 2021 Feb; 206(3):599-606. PubMed ID: 33298617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial.
    Maes B; Bosteels C; De Leeuw E; Declercq J; Van Damme K; Delporte A; Demeyere B; Vermeersch S; Vuylsteke M; Willaert J; Bollé L; Vanbiervliet Y; Decuypere J; Libeer F; Vandecasteele S; Peene I; Lambrecht B
    Trials; 2020 Jun; 21(1):468. PubMed ID: 32493441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019: Survival and Clinical Outcomes.
    Price CC; Altice FL; Shyr Y; Koff A; Pischel L; Goshua G; Azar MM; Mcmanus D; Chen SC; Gleeson SE; Britto CJ; Azmy V; Kaman K; Gaston DC; Davis M; Burrello T; Harris Z; Villanueva MS; Aoun-Barakat L; Kang I; Seropian S; Chupp G; Bucala R; Kaminski N; Lee AI; LoRusso PM; Topal JE; Dela Cruz C; Malinis M
    Chest; 2020 Oct; 158(4):1397-1408. PubMed ID: 32553536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A retrospective matched cohort single-center study evaluating outcomes of COVID-19 and the impact of immunomodulation on COVID-19-related cytokine release syndrome in solid organ transplant recipients.
    Ringer M; Azmy V; Kaman K; Tang D; Cheung H; Azar MM; Price C; Malinis M
    Transpl Infect Dis; 2021 Apr; 23(2):e13556. PubMed ID: 33378571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tocilizumab for the treatment of adult patients with severe COVID-19 pneumonia: A single-center cohort study.
    Fernández-Ruiz M; López-Medrano F; Pérez-Jacoiste Asín MA; Maestro de la Calle G; Bueno H; Caro-Teller JM; Catalán M; de la Calle C; García-García R; Gómez C; Laguna-Goya R; Lizasoáin M; Martínez-López J; Origüen J; Pablos JL; Ripoll M; San Juan R; Trujillo H; Lumbreras C; Aguado JM
    J Med Virol; 2021 Feb; 93(2):831-842. PubMed ID: 32672860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.